Fraternale A, Paoletti MF, Casabianca A, Oiry J, Clayette P, Vogel JU, Cinatl J Jr, Palamara AT, Sgarbanti R, Garaci E, Millo E, Benatti U, Magnani M
Sahni and our team are here to help you achieve meaningful and lasting improvements in your health and quality of life
Prescription rates have surged following FDA approvals of newer agents like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound)
The post lists a type 2 diabetes diagnosis with inadequate control on other medications, or a BMI at or above 27 combined with weight-related comorbidities such as hypertension, sleep apnea or cardiovascular disease
Some find this dose sufficient for their goals and maintain it long-term